Abstract: Hypertension and rheumatoid arthritis are regarded as a conditions associated with higher risk for cardiovascular disease. As known endothelial dysfunction is an early pathophysiological feature and an independent predictor cardiovascular disease. L-arginine is the amino acid with potential to improve endothelial function and is expected to play a role in the prevention or treatment of cardiovascular disease. In addition, data exists that L-arginine aspartate can reduce insulin resistance. We aimed to evaluate the effects of oral L-arginine supplementation on cardiometabolic factors by determining endothelial function, insulin resistance, adiponectin level in hypertensive patients combined with rheumatoid arthritis and its relationship with body mass index. 69 females with mean age -54 [50,3; 61,5] years were enrolled. The 1 st group made up 29 patients with hypertension combined with rheumatoid arthritis, 2 nd group -20 patients with rheumatoid arthritis, 3 rd group -20 patients with hypertension. In the endpoint patients were randomized to study subgroups patients, which received L-Arginine aspartate 30 ml/day during 4 weeks in addition to standard treatment, and control subgroups -received only the standard treatment. The levels of total cholesterol, triglycerides, C-reactive protein, serum creatinine, body mass index, body area index were determined. Insulin resistance, adiponectin level, endothelial-dependent flow mediated vasodilatation of brachial artery were measured at baseline and after 4 weeks. In patients with hypertension combined with rheumatoid arthritis identified a significant increase in insulin levels, insulin resistance, adiponectin, which were associated with cardiovascular risk, abdominal obesity, inflammatory activity levels. Oral supplementation of L-arginine causes multiple beneficial effects on the complex of cardiometabolic factors including: endothelial dysfunction, peripheral insulin resistance, adiponectin level in hypertensive patients with rheumatoid arthritis, mainly in obesity case. With the correction of endothelial function were established more significantly changes in the investigated parameters.
INTRODUCTION
Improvements in rheumatoid arthritis (RA) treatments have resulted in increases in median life expectancy for this persons. Older RA patients now face the same medical conditions associated with aging in the general population, including cardiovascular disease (CVD) [1] . On the other hand, RA should be regarded as a condition associated with higher risk for CV disease and the key feature explaining this increased CV risk seems to be inflammation [2, 17] . Therefore, experts EULAR in 2010 published recommendations for management of patients with cardiovascular risk in RA [2] .
Hypertension (HT) is quantitatively the most important modifiable risk factor for CVD seems highly prevalent in RA. The frequency of hypertension in RA varies from 18 to 70.5% according to different data [3] . It was noted in RA patients frequent (46%) and early formation of isolated systolic HT [4, 5] , the most unfavorable in terms of cardiovascular complications, which is higher than prevalence in general population [6] . According to these facts cardiovascular risk management in HT patients combined with RA seems to be important for the fatal cardiovascular events prevention. Limited predictive value of traditional factors in HT patients in combination with RA, and the inconsistency of their impact, complexity of verification of atherosclerotic vascular lesions in RA necessitates the introduction into clinical practice of additional markers of cardiovascular risk and finding ways to influence them [7] .
The cardiometabolic syndrome, an interesting constellation of cardiovascular, renal, metabolic, prothrombotic, and inflammatory abnormalities, widely discussed in the recent literature. Co-morbidities common in RA, such as insulin resistance, dyslipidaemia, adipose tissue metabolic disorders and obesity [8, 9, 18] have been shown to associate with essential HT and cardiometabolic syndrome in the general population [10, 19] . Obesity is highly prevalent in RA especially abdominal obesity. It is now recognized that adipose tissue is dynamic and metabolically active organ that secretes a number of bioactive molecules called adipokines [11] , which may play a role in the development of atherogenesis in patients with RA [12] . A special role in cardiometabolic continuum, including in RA patients is given to adiponectin, positioned as an additional marker of cardiovascular risk [12] . However, it is unknown whether RA changes the influence of adipokines on cardiovascular metabolic risk [13] .
Endothelial dysfunction is highly prevalent in RA [24] and considered as a link between cardiometabolic factors leading to the initial stage of cardiovascular continuum [15, 22] . Endothelial dysfunction initiates early atherogenesis and contributes to the development of clinical features in the later stages of the vascular disease including progression of the atherosclerotic plaque [28] . Endothelial dysfunction may be determined as an impaired ability of the artery to dilate in response to physical and chemical stimuli due to a decreased released or increased breakdown of NO [29] . This impaired NO bioavailability and RA disease-related inflammation leads to impairment in endothelium dependent vasodilatation in this patients [30] . These facts causes the search for ways of endothelial dysfunction correction in HT patients with RA [24] . L-arginine is a nutritionally important amino acid that have a wide spectrum of functions in various metabolic processes. L-arginine is a precursor for nitric oxide (NO), and thus takes part in regulation of endothelial function [14, 21] . In addition, Dong et al. in meta-analysis demonstrated that L-arginine aspartate can reduce insulin resistance. Considering these properties it may be beneficial L-arginine aspartate using in HT patients with RA. We aimed to evaluate the effects of oral l-arginine supplementation on cardiometabolic factors by determining endothelial function, insulin resistance, adiponectin level in hypertensive patients combined with RA and its relationship with body mass index.
PATIENTS AND METHODS

Patients
The present study was conducted with approval from the Ethics Committee at State Establishment «Dnipropetrovsk Medical Academy of Health Ministry of Ukraine» according to the principles outlined in the Helsinki declaration. 
Assessments
Height, weight, and waist and hip circumference were measured using standard approaches. Overall adiposity, abdominal obesity, and fat distribution were estimated by the body mass index (BMI), waist circumference, and waist-hip ratio, respectively. We assessed systolic blood pressure (SBP), diastolic blood pressure (DBP), disease activity for RA by the Disease Activity Score for 28 joints based on erythrocyte sedimentation rate (DAS28-ESR). C-reactive protein concentrations were determined using immunoturbidimetric methods. Standard laboratory blood tests of erythrocyte sedimentation rate, renal and liver function, hematological parameters, lipids, and glucose were performed. The glomerular filtration rate was estimated using the CKD-EPI formula. Cardiovascular risk was assessed by SCORE models adapted for patients with RA by introducing a 1.5 multiplication factor and total cholesterol/HDL cholesterol ratio according to EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis.
Insulin and adiponectin concentrations were measured at the baseline and after 4 weeks using solid-phase sandwich enzyme-linked immunosorbent assays (ELISA) (DRG, Germany and ASSAYPRO, USA respectively). Normal adiponectin concentration in blood serum was considered 3-14 ng/mL, insulin -2 -25 IU/mL. The level of insulin resistance, function of pancreas cells, peripheral tissue sensitivity to insulin index were calculated using the standard formula HOMA1 (E. Bonora, 1998), HOMA2 (Wallace T, 2004) using HOMA 2 Calculator Version 2.2.2. HOMA1-IR values above 2.77 and HOMA2-IR above 1.00 testified insulin resistance. Using both indices HOMA1, HOMA2 was due to the lack of clear guidance of the insulin resistance model using in patients with HT with RA. Determination of flow mediated vasodilation of brachial artery was performed at the baseline and after 4 weeks based on Celermajer's recommendation (1992) . The diameter of the brachial artery was measured with 7.5 MHz transducer of «Philips Envisor C».
Study Design
In the endpoint patients were prospectively randomly and blindly divided into study group patients, which received L-Arginine aspartate (Tivortin, "YuriyaFarm", Kiev, Ukraine) in an oral solution 30 ml/day during 4 weeks (average period evaluating the effectiveness according to the literature) in addition to standard treatment, and control group -received only the standard treatment. Patients also were devided into three groups depending on HT and RA comorbidity to study cardiometabolic risk features in combining of these nosology. 
Statistical Analysis
Statistical computations were made using the Statistica program v. 6.1. (StatSoft Inc.), and «Excel 2013» (Microsoft). Data are shown as number of subjects (%) or median (interquartile range [IQR] ) because data were not normal distribution. The Mann -Whitney U-test and Wilcoxon test were used to analyze differences between two independent and dependent groups respectively. Correlation coefficient Spearmen (R) was calculated. A p value < 0.05 was considered statistically significant.
RESULTS
Patient Characteristics
Baseline characteristics in study patients are given in Table 1 . In the HT+RA group in compare with RA group there were significant higer BMI (p<0.001), waist circumference (p<0.001) waist-hip ratio (p<0.001) wherein this group of patients were more often obesity (p<0.001). BMI was highly correlated in hypertensive RA patients with GFR (R = 0.38 (p<0.05), duration of glucocorticoids therapy (R = 0.50 (p<0.05), insulin level (R = 0.40 (p<0.05) and insulin resistance matched by HOMA-1 and HOMA-2 models (R = 0.47 (p<0.05), R = 0.44 (p<0.05), respectively).
HT patients with RA characterized by significant 5 times higer SCORE level in compare with RA group (p=0.02). Analyzing cardiometabolic factors has been (R=0,27, <0,05) . According to our data use of the model HOMA2-IR, perhaps more fully reflects the presence of insulin resistance and its association to patients with hypertension combined with RA. Data demonstrates increased functional activity of the pancreas insular part, and significant decrease in peripheral insulin receptors sensitivity in HT+RA group patients.
After 4 weeks of treatment with L-Arginine mean EDVD was increased by 23.2% on the whole (p<0.001), in compare with standard therapy -on 20.2% (p=0.03). Paradoxical vasoconstriction was The level of insulin to the end of the study was lower on 9.3% (p=0.004), insulin resistance -on 7.9% (p=0.004) matched by 1-IR and on 18.7% (p=0.002) matched by 2-IR among patients received L-Arginine aspartate. Thus the insulin resistance correction in this patients was mainly due to increase the sensitivity of insulin receptors, as evidenced by the dynamics of indicators HOMA2-%B, HOMA2-%S --4.3% ( =0,003) and +15.5% ( <0,001) respectively ( Table 4 ). In the standard treatment group these parameters in the dynamics weren't differ significantly. (Figure 1) . Should be noted tends to reduce the level of adiponectin in patients received L-arginine aspartate (p=0.06), wherein maximal dynamic observed in HT patients with RA -on 4.2% (p=0.06) (Figure 1) . Table 3) . In patients with endothelial dysfunction correction observed a significant decrease of adiponectin in compare to preserved endothelial dysfunction patients on 11.2 % (p=0.04).
DISCUSSION
As known in the pathogenesis of accelerated atherosclerosis in RA a major issue is the development of endothelial activation, which leads to endothelial dysfunction a premature atherosclerosis in these patients [31] . Increased levels of circulating inflammatory mediators might cause activation and damage of endothelial cells in patients with RA that leads to decreasing of NO formed from the amino acid L-arginin [32] . Endothelial derived NO participates in several atheroprotective functions such as relaxing vascular smooth muscle cells, inhibition of platelet and leukocyte adhesion to vascular endothelium, inhibition of the vascular smooth muscle cell migration and growth, and limiting the oxidation of atherogenic low density lipoproteins in addition to its effect on vessel tone and blood pressure [33, 34] . Reduced bioavailability of NO is considered the key feature of endothelial dysfunction in HT also. HT and RA combination appears to have a complex association with endothelial dysfunction, a phenotypical alteration of the vascular endothelium that precedes the development of adverse cardiovascular events and portends future cardiovascular risk [22] .
Cause-and-effect relationship of endothelial dysfunction and insulin resistance are debated. Many studies have shown that endotelial dysfunction is a consequence of the mechanisms underlying the insulin resistance -hyperglycemia, HT, dyslipidemia [28] .Without a doubt, insulin resistance and endotelial dysfunction are closely linked and form abnormal "vicious circle". Despite still uncertainty causal relationships in the pathogenesis of endotelial dysfunction, it is indisputable that it's the first step in the development of atherosclerosis, which is associated with the insulin resistance. Therefore, further study of endothelial dysfunction and methods of its correction is implicitly relevant. Current data support a complex relationship of endothelial dysfunction and cardiometabolic factors in HT, RA presence. According to our data, endothelial function was significantly lower in comorbidity of HT and RA and was associated mainly with abdominal obesity, inflammation activity and renal function. Perhaps this may indicate a relationship with metabolic factors such as the adipose tissue exchange. Thus, as endothelial dysfunction is one of the early stages of atherosclerosis, it is reasonable to consider that substances secreted by adipose tissue may influence directly or indirectly (for instance by induction of microinflammation) the function of endothelial cells. Inflammation in adipose tissue, apparent in visceral fat depots, is associated with impaired endothelial function in obese patients [21] . On the other hand RA characterized by high prevelance of obesity and endothelial dysfunction in the development plays an important role contradictory impact medication of RA. To understand the cardiometabolic abnormalities features in present study, the differences between groups divided according to the comorbidity of HT and RA may form the certain conclusions. HT patients with RA presents significant higer prevalence of abdominal obesity, endothelial dysfunction, dyslipidemia, insulin resistance, adipose tissue metabolic disturbance that needs correction.
The main message of the present study is that the correction and expectly normalizing of endothelial dysfunction in HT patients with RA with L-Arginine aspartate supplementation may caused benefit effects on range of cardiometabolic factors. Current obtained data may indicate the key role of endothelial function in reducing the sensitivity of peripheral insulin receptors and adiposity dysfunction in HT patients with RA, which requires more detailed study. As such, assessments of endothelial function on example of L-Arginine aspartate supplimentation could prove to be useful tools in the identification and monitoring of cardiometabolic risk in HT patients with RA. It should be noted that the increase in insulin sensitivity under the influence of Larginine is also noted in other studies. Thus, R. Lucotti et al. [26] in a randomized, double-blind study involving 64 patients with CVD without diabetes after coronary artery grafting bypass orally for 6 months L-arginine at a dose of 6.4 g/day, established EDVD increase (p<0.01), decrease in insulin resistance (p<0.05) and increased adiponectin levels (p <0.01). In a study conducted Piatti P M. et al. oral administration of 9 grams/day of L-arginine for 1 month in patients with type 2 diabetes has led to a significant increase in forearm blood flow (36%), normalization initially reduced cGMP level, decrease in systolic blood pressure by 14% and improved sensitivity to insulin [27] . In 2011 Dong, J.Y. et al. published meta-analysis of 11 randomized, double-blind, placebo-controlled trials used oral L-arginine supplementation showed possible insulin resistance reducing effect [16] .
Including L-Arginine aspartat in complex therapy in HT patients with RA appear to have added benefits with respect to endothelial function, but whether these benefits translate into improved outcomes remains unknown. Answers to these questions gained through future investigations may give us the knowledge to develop and implement novel interventions and strategies to reduce the morbidity and mortality of HT patients with RA. The dynamics EDVD increase, decrease HOMA index may indicate confirmation that endothelial dysfunction is the "cornerstone" of not only HT patients with RA progression, but also the development of metabolic changes that accompany it.
LIMITATIONS
However, the results of this study should be interpreted with caution because of several limitations. Therefore, only female subjects were chosen for this study, and consequently the results can only be applied to the female gender. The study was carried out in a 4-weeks period, and as that time was not enough for adequate evaluation of hard end points, such as insulin resistance and adiponectin normalisation, the study assesses only intermediate end points. However, it cannot be established from the present study whether the changes observed were permanent or reversible. In this regard, more prolonged L-arginine supplimentation study in hypertensive patients with rheumatoid arthritis requires.
CONCLUSIONS
1.
In hypertensive patients with rheumatoid arthritis identified a significant increase of insulin levels, insulin resistance, adiponectin, which were associated with cardiovascular risk, abdominal obesity, inflammatory activity.
2.
Oral supplementation of L-arginine causes multiple beneficial effects on the complex of cardiometabolic factors including: endothelial dysfunction, peripheral insulin resistance, adipose tissue exchange in hypertensive patients with rheumatoid arthritis, mainly in obesity case. With the correction of endothelial function were established more significantly changes in the investigated parameters.
